Clinical Trial Update: Safety Study of Anti-IgE Immunotherapy in Allergic Patients [Phase 2]

View source ↗

Summary

A Phase 2 safety trial of anti-IgE immunotherapy in allergic patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases

Drugs mentioned

• Anti-IgE immunotherapy

Snippet

Sponsor: Resistentia Pharmaceuticals AB | Conditions: Allergy | Phase 2 | Status: COMPLETED